trending Market Intelligence /marketintelligence/en/news-insights/trending/9u2HmK2Euz1EAyeW-LTFYQ2 content esgSubNav
In This List

Merck's Keytruda fails as 2nd line treatment for gastric cancer in phase 3 trial

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Merck's Keytruda fails as 2nd line treatment for gastric cancer in phase 3 trial

Merck & Co. Inc.'s phase 3 trial of Keytruda as a second-line treatment for a certain gastric cancer failed to meet its main goal of overall survival.

The KEYNOTE-061 study was evaluating Keytruda as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1.

In addition, progression free survival in the PD-L1 positive population did not show statistical significance.

Merck will continue to evaluate Keytruda as a monotherapy or in combination with chemotherapy in another phase 3 trial, KEYNOTE-062, as first-line treatment for patients with PD-L1 positive advanced gastric or gastroesophageal junction cancer.

In September, the U.S. Food and Drug Administration approved Keytruda as a third-line treatment for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express PD-L1.